Aakaar Medical Technologies Ltd
Incorporated in June 2013, Aakaar Medical Technologies Limited is an aesthetic medical company that offers a diverse selection of specialized cosmetic products and devices.[1]
- Market Cap ₹ 102 Cr.
- Current Price ₹ 71.7
- High / Low ₹ 90.0 / 46.0
- Stock P/E 9.27
- Book Value ₹ 41.0
- Dividend Yield 0.00 %
- ROCE 18.5 %
- ROE 17.1 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 65.2% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 203 days.
- Working capital days have increased from 130 days to 199 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Personal Products Personal Care
Part of Nifty SME Emerge
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 23 | 12 | 19 | 33 | 46 | 62 | 67 | 85 | |
| 20 | 12 | 17 | 29 | 41 | 52 | 57 | 70 | |
| Operating Profit | 3 | 1 | 2 | 4 | 5 | 10 | 10 | 16 |
| OPM % | 13% | 7% | 12% | 11% | 11% | 16% | 15% | 19% |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 1 | 2 | 3 | 4 | 8 | 9 | 15 |
| Tax % | 27% | 29% | 26% | 31% | 26% | 26% | 28% | |
| 2 | 1 | 2 | 2 | 3 | 6 | 7 | 11 | |
| EPS in Rs | 2.01 | 0.59 | 1.78 | 2.36 | 3.15 | 5.79 | 4.69 | 7.74 |
| Dividend Payout % | 0% | 0% | 35% | 24% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 40% |
| 3 Years: | 27% |
| TTM: | 44% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 65% |
| 3 Years: | 46% |
| TTM: | 129% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 23% |
| Last Year: | 17% |
Balance Sheet
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.10 | 0.10 | 0.70 | 0.70 | 0.70 | 10 | 14 | 14 |
| Reserves | 7 | 7 | 7 | 9 | 12 | 13 | 40 | 44 |
| 6 | 4 | 4 | 6 | 15 | 23 | 19 | 19 | |
| 4 | 3 | 6 | 8 | 6 | 8 | 6 | 12 | |
| Total Liabilities | 16 | 14 | 18 | 23 | 34 | 54 | 79 | 88 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 16 | 14 | 18 | 23 | 34 | 54 | 79 | 87 | |
| Total Assets | 16 | 14 | 18 | 23 | 34 | 54 | 79 | 88 |
Cash Flows
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| -0 | 4 | 0 | -3 | -8 | -5 | -8 | |
| 0 | 0 | -0 | -0 | -0 | -0 | 0 | |
| 0 | -2 | -1 | 1 | 8 | 11 | 19 | |
| Net Cash Flow | 0 | 3 | -1 | -2 | 0 | 5 | 10 |
| Free Cash Flow | -0 | 4 | 0 | -3 | -8 | -5 | -9 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 10% | 503% | 47% | -54% | -136% | -35% | -59% |
Ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 118 | 136 | 104 | 114 | 129 | 166 | 203 |
| Inventory Days | 234 | 366 | 282 | 274 | 247 | 202 | 256 |
| Days Payable | 28 | 99 | 65 | 62 | 32 | 49 | 24 |
| Cash Conversion Cycle | 324 | 403 | 321 | 326 | 344 | 320 | 434 |
| Working Capital Days | 189 | 238 | 105 | 102 | 94 | 97 | 199 |
| ROCE % | 8% | 21% | 26% | 23% | 27% | 18% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Number of Doctors Using Multiple Brands (Cross-sell Total) count |
|
||||
| Number of Field Force (MR Executives) count |
|||||
| Number of SKUs count |
|||||
| Own Brand Share of Revenue % |
|||||
| Number of Customers (Doctors/Clinics Billed) count |
|||||
| Top 10 Own Products Share of Revenue % |
|||||
| Number of Stockists count |
|||||
Extracted by Screener AI
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
- H1 FY27 earnings call transcript disclosed revenue of INR43.99 crore and PAT of INR3.54 crore on October 30, 2026.
-
Analysts/Institutional Investor Meet/Con. Call Updates
- Audio recording of half-year FY26-27 earnings call uploaded on company website on October 30, 2026.
-
Outcome of Board Meeting
- Board approved H1 FY2027 results, 186,720 ESOPs, and Abhash Meswani’s WTD/director appointment from 1 Nov 2026.
-
Outcome of Board Meeting
- Board approved H1 FY27 results, 186,720 ESOPs, and Abhash Meswani’s appointment from 1 November 2026.
-
Investor Presentation
- Board approved H1 FY27 results; revenue rose 72.6% to ₹43.72 Cr, PAT ₹3.54 Cr.
Concalls
-
Nov 2026Transcript PPT REC
-
Jun 2026PPT
-
May 2026Transcript PPT REC
-
Nov 2025Transcript PPT
Business Overview:[1]
AMTL is a doctor-focused medical aesthetics company dealing in a wide range of aesthetics products and medical devices. The company operates primarily through B2B channels, supplying dermatologists, plastic surgeons, aesthetic physicians, and clinics across India. It became India's first medical aesthetics company to be listed on the NSE Emerge platform.